(Q35553616)

8 August 2017

1 reference

title

The evolving role of docetaxel in the management of androgen independent prostate cancer (English)

1 reference

8 August 2017

The Evolving Role of Docetaxel in the Management of Androgen Independent Prostate Cancer (English)

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

19 March 2024

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

19 March 2024

3

Alan W Partin

1 reference

8 August 2017

Masood A. Khan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14532760

19 March 2024

Michael A. Carducci

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14532760

19 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

http://api.elsevier.com/content/article/PII:S0022534705629175?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

http://api.elsevier.com/content/article/PII:S0022534705629175?httpAccept=text/plain

19 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

http://www.jurology.com/doi/pdf/10.1097/01.ju.0000088787.95124.4b

19 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

19 March 2024

1 reference

8 August 2017

volume

170

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

1709-1716

1 reference

Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

19 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases

19 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer

19 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Critical evaluation of hormonal therapy for carcinoma of the prostate

19 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

19 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

19 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Targeting apoptosis in prostate cancer

19 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells

19 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis.

19 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

19 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

19 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

19 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

19 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Taxol (paclitaxel): mechanisms of action

19 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Taxol: an antimitotic agent with a new mechanism of action

19 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma

19 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer

19 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Inactivation of Bcl-2 by phosphorylation

19 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Taxol induces bcl-2 phosphorylation and death of prostate cancer cells

19 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Immunohistochemical analysis of in vivo patterns of Bcl-X expression

19 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

19 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

19 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results

19 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

19 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2

19 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

19 March 2024

36

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

19 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer

19 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report

19 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results

19 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Severe interstitial pneumonitis associated with docetaxel administration.

19 March 2024

43

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Intestinal side-effects of docetaxel/vinorelbine combination

19 March 2024

44

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer

19 March 2024

46

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Nail changes due to docetaxel

19 March 2024

47

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

19 March 2024

48

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer

19 March 2024

50

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

19 March 2024

51

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

19 March 2024

52

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer

19 March 2024

53

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis

19 March 2024

56

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease

19 March 2024

59

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Weekly high-dose calcitriol and docetaxel in advanced prostate cancer

19 March 2024

68

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer

19 March 2024

70

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Prostate cancer: multimodality approaches with docetaxel

19 March 2024

71

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.

19 March 2024

72

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts

19 March 2024

73

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

The impact of tumor cell proliferation in radioimmunotherapy.

19 March 2024

74

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000088787.95124.4B

19 March 2024

Identifiers

1 reference

8 August 2017

1 reference